EUCTR2007-005396-34-GB进行中（未招募）不适用
Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphomaof the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL) - Euro-LB 02
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 173
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?lymphoblastic lymphoma diagnosed either by histomorphological or cytomorphological characterisation
- •?age < 22 years (i.e. up to but not including the 22nd birthday)
- •?signed informed consent of patient/parents/guardians for participation
- •?National and local ethical and regulatory approval of this protocol
- •?No evidence of pregnancy or breast feeding
- •?No participation in another clinical study
- •?Pathological material to be made available for Central Histological Review
- •?Potential follow up of at least 36 months duration
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?HIV infection or AIDS
- •?severe immunodeficiency
- •?previous organ transplantation
- •?previous malignancy
- •?pre-existing disease prohibiting chemotherapy as per instructions of the Protocol
- •?previous chemotherapy or radiotherapy
- •?previous systemic corticosteroid treatment for more than 8 days within two months before the beginning of therapy according to this Protocol EURO-LB 02
研究者
相似试验
进行中（未招募）
1 期
B cell therapy followed by T cell therapy to achieve immune tolerance in rheumatoid arthritis with ACPA antiboidies (TOLERA): an unblinded clinical trial in one centre with random assignment to treatment groups in adult patients who failed methotrexate therapyActive rheumatoid arthritis with ACPA antibodies failing methotrexateMedDRA version: 23.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2018-003877-91-DEniversitätsklinikum Erlangen20
进行中（未招募）
1 期
Cell based treatment in combination with checkpoint inhibitors for ovarian-, fallopian tube and primary peritoneal cancer.EUCTR2017-002179-24-DKCenter for Cancer Immune Therapy6
招募中
1 期
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS)Sporadic Amyotrophic Lateral SclerosisMedDRA version: 21.1Level: PTClassification code: 10002026Term: Amyotrophic lateral sclerosis Class: 100000004852CTIS2022-502743-35-00Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.52
招募中
2 期
B-cell depletion for the treatment of patients with amyotrophic lateral sclerosis (ALS) - A Randomized, Double-blind, Placebo controlled Pilot Study in Patients with Amyotrophic Lateral Sclerosis for the Evaluation of Efficacy and Safety of B-Cell Depletion with Rituximab (ABCD)G12.2Motor neuron diseaseDRKS00030948Deutsches Zentrum für Neurodegenerative Erkrankungen e.v.65
进行中（未招募）
1 期
Cell based immune therapy for patients with skincancermalignant melanomaMedDRA version: 18.1Level: LLTClassification code 10027481Term: Metastatic melanomaSystem Organ Class: 100000004864EUCTR2014-001420-29-DKCenter for Cancer Immune Therapy20